BACKGROUND: Ophthalmic artery chemosurgery (OAC) is associated with grade 3 and 4 neutropenia, however the effect on T-cell number and function is unknown. The purpose of this retrospective review was to confirm that patients treated with OAC do not develop immunosuppression warranting Pneumocystis pneumonia prophylaxis. PROCEDURE: IRB approval was obtained for a single center retrospective review of immune function tests in retinoblastoma patients who received OAC. RESULTS: Twenty-three patients received ≥3 cycles of OAC and had immune function testing (absolute CD4 count) performed at a median of 34 days postcompletion of therapy (range, 15 to 63 d). Only 1 patient had a low absolute CD4 count of 189 cells/μL (normal, 359 to 1570 cells/μL) 2 and a half months after IV carboplatin and 28 days after their third dose of OAC. This patient was found to have coexisting hypogammaglobulinemia. Repeat immune function testing normalized through continued OAC treatment. CONCLUSIONS: Clinically significant immune suppression appears rare following OAC alone, but patients previously treated with IV chemotherapy may be immunosuppressed and may benefit from pneumocystis pneumonia prophylaxis until the CD4 count recovers.
BACKGROUND: Ophthalmic artery chemosurgery (OAC) is associated with grade 3 and 4 neutropenia, however the effect on T-cell number and function is unknown. The purpose of this retrospective review was to confirm that patients treated with OAC do not develop immunosuppression warranting Pneumocystis pneumonia prophylaxis. PROCEDURE: IRB approval was obtained for a single center retrospective review of immune function tests in retinoblastomapatients who received OAC. RESULTS: Twenty-three patients received ≥3 cycles of OAC and had immune function testing (absolute CD4 count) performed at a median of 34 days postcompletion of therapy (range, 15 to 63 d). Only 1 patient had a low absolute CD4 count of 189 cells/μL (normal, 359 to 1570 cells/μL) 2 and a half months after IV carboplatin and 28 days after their third dose of OAC. This patient was found to have coexisting hypogammaglobulinemia. Repeat immune function testing normalized through continued OAC treatment. CONCLUSIONS: Clinically significant immune suppression appears rare following OAC alone, but patients previously treated with IV chemotherapy may be immunosuppressed and may benefit from pneumocystis pneumonia prophylaxis until the CD4 count recovers.
Authors: Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie Journal: Nat Rev Dis Primers Date: 2015-08-27 Impact factor: 52.329
Authors: Ira J Dunkel; Weiji Shi; Kim Salvaggio; Brian P Marr; Scott E Brodie; Y Pierre Gobin; David H Abramson Journal: PLoS One Date: 2014-10-10 Impact factor: 3.752
Authors: Sruti S Akella; Jasmine H Francis; Andrea Knezevic; Irina Ostrovnaya; Y Pierre Gobin; Danielle Friedman; Edith Guarini; Lindsey Eibeler; Federica Catalanotti; David H Abramson Journal: PLoS One Date: 2018-05-07 Impact factor: 3.240
Authors: Anthony B Daniels; Michael T Froehler; Amy H Nunnally; Janene M Pierce; Ivan Bozic; Cameron A Stone; Pranav R Santapuram; Yuankai K Tao; Kelli L Boyd; Lauren E Himmel; Sheau-Chiann Chen; Liping Du; Debra L Friedman; Ann Richmond Journal: Invest Ophthalmol Vis Sci Date: 2019-03-01 Impact factor: 4.799
Authors: Anthony B Daniels; Michael T Froehler; Jessica V Kaczmarek; Carley M Bogan; Pranav R Santapuram; Janene M Pierce; Sheau-Chiann Chen; Emma A Schremp; Kelli L Boyd; Yuankai K Tao; Marion W Calcutt; Tatsuki Koyama; Ann Richmond; Debra L Friedman Journal: Transl Vis Sci Technol Date: 2021-09-01 Impact factor: 3.283
Authors: Paula Schaiquevich; Jasmine H Francis; María Belén Cancela; Angel Montero Carcaboso; Guillermo L Chantada; David H Abramson Journal: Front Oncol Date: 2022-04-01 Impact factor: 5.738